This activity is supported by an educational grant from

Mathias J. Rummel, MD, PhD
Head, Department for Hematology
Hospital of the Justus-Liebig University
Gießen, Germany

Bio

• Understand the rationale for the development and integration of treatment strategies in NHL
• Examine clinical trial results of treatment regimens, both containing novel agents and combinations, in patients with NHL
• Discuss phase III clinical trial results which have a direct implication on the management of patients with indolent and mantle cell lymphomas with respect to efficacy and toxicity parameters

Target Audience
The intended audience for this initiative is community-based medical oncologists, hematologist-oncologists, thoracic surgeons, radiation oncologists, pathologists, and oncology pharmacists caring for patients with NHL.

Statement of Need
An estimated 65,980 new cases of NHL were diagnosed in the United States in 2009. Despite treatment advancements for these hematologic malignancies, an estimated 19,500 will die secondary to NHL. Expected cases of NHL in 2009 slightly decreased since 2008; however, the number of deaths is expected to increase. It is well-noted that Canada and European countries are able to accrue participants for clinical trials faster than the United States for a myriad of reasons, and significant data regarding the treatment of hematologic malignancies has been derived from large phase III clinical trials conducted in Europe and Canada. Clinical results from European and Canadian trials are continually highlighted in the published literature and national/international meetings. US-based practitioners, charged with the care of patients with NHL, must have in-depth knowledge of current preclinical and clinical data in order to make the most appropriate treatment-related decisions for his/her patients and must understand the placement of said data in the context of the American patient.

ACCREDITATION INFORMATION
PHYSICIAN CONTINUING EDUCATION
Accreditation Statement
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION
	Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Educational Concepts Group, LLC designates this continuing education activity for 1.0 contact hour (0.10 CEU) (UAN 0199-0000-10-004-H01-P).

TYPE OF ACTIVITY: Knowledge-based

METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity. During the period April 22, 2010 through April 21, 2011 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assesment. Participants must view each section in its entirety to receive full credit for this program.

CME/CE Credits
Physicians and pharmacists who complete the post-test with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Cephalon Oncology.

ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.

FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.

The following faculty member has declared relevant financial relationships:

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.

DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG and FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

CME/CE INQUIRIES
For further information, please contact: Educational Concepts Group, LLC | 1300 Parkwood Circle SE | Suite 325 | Atlanta, Georgia 30339 Phone: 1.770.933.1681 | Fax: 1.770.933.1692
www.educationalconcepts.net

None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.

AUDIO/VIDEO PRESENTATION
Participants must view activity in its entirety to receive full credt for this program.

QUESTIONS?
Please contact Samra AliKhan at Educational Concepts Group, LLC
Phone: 1.866.938.2051
Fax: 1.770.933.1692
salikhan@educationalconcepts.net